GGHC
CTMX icon

Gilder Gagnon Howe & Co’s CytomX Therapeutics CTMX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.64M Sell
704,423
-415,886
-37% -$1.59M 0.03% 202
2026
Q1 		$5.27M Buy
+1,120,309
New +$5.69M 0.06% 147

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Gilder Gagnon Howe & Co's CTMX Position: Q2 2026 in Review

Gilder Gagnon Howe & Co reduced its CytomX Therapeutics (CTMX) stake by 37% in Q2 2026, selling an estimated $1.59M and leaving 704,423 shares worth $2.64M. The position accounts for 0.03% of the portfolio, ranked #202.

Gilder Gagnon Howe & Co first reported a position in CTMX in Q1 2026 and has held it in 2 quarters since. The position peaked at $5.27M in Q1 2026. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Gilder Gagnon Howe & Co held 704,423 shares of CytomX Therapeutics worth $2.64M as of Q2 2026.
  • Gilder Gagnon Howe & Co sold 415,886 CytomX Therapeutics shares in Q2 2026, an estimated $1.59M.
  • CytomX Therapeutics made up 0.03% of Gilder Gagnon Howe & Co's portfolio in Q2 2026, its #202 holding.
  • Gilder Gagnon Howe & Co first reported a position in CytomX Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Gilder Gagnon Howe & Co's CytomX Therapeutics position peaked at $5.27M in Q1 2026.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2026, filed 14 Aug 2026.